Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registry

IF 1.8 4区 医学 Q2 OTORHINOLARYNGOLOGY
Shigeharu Fujieda , Jayant M. Pinto , David W. Jang , Joseph K. Han , James Mims , Eugenio De Corso , Martin Wagenmann , Changming Xia , Thomas Plucinak , Mark Corbett , Scott Nash , Amr Radwan
{"title":"Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registry","authors":"Shigeharu Fujieda ,&nbsp;Jayant M. Pinto ,&nbsp;David W. Jang ,&nbsp;Joseph K. Han ,&nbsp;James Mims ,&nbsp;Eugenio De Corso ,&nbsp;Martin Wagenmann ,&nbsp;Changming Xia ,&nbsp;Thomas Plucinak ,&nbsp;Mark Corbett ,&nbsp;Scott Nash ,&nbsp;Amr Radwan","doi":"10.1016/j.amjoto.2024.104596","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>The global Assessing long-teRm Outcomes in dupiluMAb (AROMA) registry study aims to characterize the long-term, real-world use of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This paper reports interim analysis of the baseline characteristics for the first 303 patients enrolled in AROMA.</div></div><div><h3>Methods and materials</h3><div>AROMA is currently ongoing in adult patients with CRSwNP who initiated dupilumab for up to 36 months. This interim analysis describes baseline demographics; systemic/oral corticosteroid (SCS/OCS) and antibiotic use; disease burden; healthcare resource utilization; and medical history. All outcomes are summarized descriptively.</div></div><div><h3>Results</h3><div>As of February 2023, AROMA had enrolled 303 patients; 61.7 % had ≥1 prior surgery and 38.3 % were surgery naive. Disease burden at baseline was greatest among patients with prior surgery vs the surgery-naive group: 72.2 % vs 62.9 % had used SCS/OCS, mean University of Pennsylvania Smell Identification Test scores were 10.9 vs 19.2, 31.0 % vs 27.6 % of patients reported severe symptoms, and 47.6 %/16.6 % vs 39.7 %/16.4 % of patients were classified as having severe/very severe disease according to global physician assessment scores. Otolaryngologist/ear, nose, throat and allergist/immunologist were the most common specialties seen regularly by CRSwNP patients (52.8 % and 48.2 %, respectively) and surgery-naive patients were more likely to have visited an allergist than those with prior surgery (66.4 % vs 36.9 %).</div></div><div><h3>Conclusions</h3><div>Patients with CRSwNP in AROMA show considerable disease burden at baseline prior to treatment. Those with prior surgery had worse olfaction and an overall worse burden of disease.</div></div><div><h3>Plain language summary</h3><div>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a condition characterized by at least 12 weeks of symptoms such as nasal congestion and loss of smell, along with the presence of nasal polyps. Treatment for CRSwNP includes intranasal steroids, but if these cannot control disease, systemic steroids or sinus surgery may be required. Systemic steroids have known side effects and only provide temporary symptom improvement. Following surgery, patients may experience both symptom and polyp recurrence. Dupilumab is a monoclonal antibody that is approved for the treatment of inadequately controlled CRSwNP and can improve disease symptoms such as nasal congestion and loss of smell. This article presents the initial findings from a large global study called AROMA, which observes patients in real-world medical practice for 3 years after initiating dupilumab for CRSwNP. This analysis compares the characteristics of those in the registry who had and had not undergone prior sinonasal surgery for CRSwNP. In this analysis, patients who had previously undergone surgery to remove nasal polyps were more likely to have used steroids for CRSwNP treatment and were in worse health because of their CRSwNP condition despite having similar severity of symptoms at baseline.</div></div>","PeriodicalId":7591,"journal":{"name":"American Journal of Otolaryngology","volume":"46 2","pages":"Article 104596"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S019607092400382X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

The global Assessing long-teRm Outcomes in dupiluMAb (AROMA) registry study aims to characterize the long-term, real-world use of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This paper reports interim analysis of the baseline characteristics for the first 303 patients enrolled in AROMA.

Methods and materials

AROMA is currently ongoing in adult patients with CRSwNP who initiated dupilumab for up to 36 months. This interim analysis describes baseline demographics; systemic/oral corticosteroid (SCS/OCS) and antibiotic use; disease burden; healthcare resource utilization; and medical history. All outcomes are summarized descriptively.

Results

As of February 2023, AROMA had enrolled 303 patients; 61.7 % had ≥1 prior surgery and 38.3 % were surgery naive. Disease burden at baseline was greatest among patients with prior surgery vs the surgery-naive group: 72.2 % vs 62.9 % had used SCS/OCS, mean University of Pennsylvania Smell Identification Test scores were 10.9 vs 19.2, 31.0 % vs 27.6 % of patients reported severe symptoms, and 47.6 %/16.6 % vs 39.7 %/16.4 % of patients were classified as having severe/very severe disease according to global physician assessment scores. Otolaryngologist/ear, nose, throat and allergist/immunologist were the most common specialties seen regularly by CRSwNP patients (52.8 % and 48.2 %, respectively) and surgery-naive patients were more likely to have visited an allergist than those with prior surgery (66.4 % vs 36.9 %).

Conclusions

Patients with CRSwNP in AROMA show considerable disease burden at baseline prior to treatment. Those with prior surgery had worse olfaction and an overall worse burden of disease.

Plain language summary

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a condition characterized by at least 12 weeks of symptoms such as nasal congestion and loss of smell, along with the presence of nasal polyps. Treatment for CRSwNP includes intranasal steroids, but if these cannot control disease, systemic steroids or sinus surgery may be required. Systemic steroids have known side effects and only provide temporary symptom improvement. Following surgery, patients may experience both symptom and polyp recurrence. Dupilumab is a monoclonal antibody that is approved for the treatment of inadequately controlled CRSwNP and can improve disease symptoms such as nasal congestion and loss of smell. This article presents the initial findings from a large global study called AROMA, which observes patients in real-world medical practice for 3 years after initiating dupilumab for CRSwNP. This analysis compares the characteristics of those in the registry who had and had not undergone prior sinonasal surgery for CRSwNP. In this analysis, patients who had previously undergone surgery to remove nasal polyps were more likely to have used steroids for CRSwNP treatment and were in worse health because of their CRSwNP condition despite having similar severity of symptoms at baseline.
慢性鼻窦炎合并鼻息肉(CRSwNP)患者手术史的基线疾病特征
目的:全球dupiluMAb长期预后评估(AROMA)注册研究旨在描述dupiluMAb在慢性鼻窦炎合并鼻息肉(CRSwNP)患者中的长期、实际使用情况。本文报道了首批加入AROMA的303例患者的基线特征的中期分析。方法和材料:AROMA目前正在接受dupilumab治疗长达36个月的CRSwNP成年患者中进行。这一中期分析描述了基线人口统计数据;全身/口服皮质类固醇(SCS/OCS)和抗生素使用;疾病负担;医疗资源利用;还有病史。对所有结果进行描述性总结。结果:截至2023年2月,AROMA共入组303例患者;61.7%有≥1次手术史,38.3%为未手术史。基线时的疾病负担在有手术史的患者中最大:72.2%比62.9%使用过SCS/OCS,宾夕法尼亚大学嗅觉识别测试的平均得分为10.9比19.2,31.0%比27.6%的患者报告了严重症状,47.6% / 16.6%比39.7% / 16.4%的患者根据全球医生评估得分被分类为严重/非常严重的疾病。耳鼻喉科/耳鼻喉科和过敏症科/免疫学家是CRSwNP患者最常去看的专科(分别为52.8%和48.2%),未接受手术的患者比有过手术的患者更有可能去看过敏症科医生(66.4%对36.9%)。结论:在治疗前的基线时,AROMA中的CRSwNP患者表现出相当大的疾病负担。那些先前做过手术的人嗅觉更差,总体上疾病负担更重。摘要:慢性鼻窦炎伴鼻息肉(CRSwNP)是一种以至少12周的鼻塞、嗅觉丧失以及鼻息肉等症状为特征的疾病。CRSwNP的治疗包括鼻内类固醇,但如果这些不能控制疾病,可能需要全身类固醇或鼻窦手术。全身类固醇有已知的副作用,只能暂时改善症状。手术后,患者可能会出现症状和息肉复发。Dupilumab是一种单克隆抗体,被批准用于治疗控制不充分的CRSwNP,可以改善鼻塞和嗅觉丧失等疾病症状。本文介绍了一项名为AROMA的大型全球研究的初步发现,该研究观察了使用dupilumab治疗CRSwNP的患者在现实世界的医疗实践中3年的情况。该分析比较了登记处中那些因CRSwNP而接受过和未接受过鼻窦手术的患者的特征。在这项分析中,先前接受过鼻息肉手术的患者更有可能使用类固醇进行CRSwNP治疗,尽管在基线时症状的严重程度相似,但由于CRSwNP状况,他们的健康状况更差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American Journal of Otolaryngology
American Journal of Otolaryngology 医学-耳鼻喉科学
CiteScore
4.40
自引率
4.00%
发文量
378
审稿时长
41 days
期刊介绍: Be fully informed about developments in otology, neurotology, audiology, rhinology, allergy, laryngology, speech science, bronchoesophagology, facial plastic surgery, and head and neck surgery. Featured sections include original contributions, grand rounds, current reviews, case reports and socioeconomics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信